251 related articles for article (PubMed ID: 24714359)
1. Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
Shi SB; Tang XY; Tian J; Chang CX; Li P; Qi JL
J Immunother; 2014 May; 37(4):250-5. PubMed ID: 24714359
[TBL] [Abstract][Full Text] [Related]
2. Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).
Zhao Y; Qiao G; Wang X; Song Y; Zhou X; Jiang N; Zhou L; Huang H; Zhao J; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Transl Oncol; 2019 Jun; 21(6):721-728. PubMed ID: 30374838
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
5. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer.
Shi SB; Ma TH; Li CH; Tang XY
Tumori; 2012; 98(3):314-9. PubMed ID: 22825506
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer.
Yuanying Y; Lizhi N; Feng M; Xiaohua W; Jianying Z; Fei Y; Feng J; Lihua H; Jibing C; Jialiang L; Kecheng X
Cryobiology; 2013 Oct; 67(2):235-40. PubMed ID: 23948179
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
8. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
Casal Rubio J; Fírvida-Pérez JL; Lázaro-Quintela M; Barón-Duarte FJ; Alonso-Jáudenes G; Santomé L; Afonso-Afonso FJ; Amenedo M; Huidobro G; Campos-Balea B; López-Vázquez MD; Vázquez S
Cancer Chemother Pharmacol; 2014 Mar; 73(3):451-7. PubMed ID: 24352251
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with sequential cytokine-induced killer (CIK) cells in stage IB non-small cell lung cancer.
Li DP; Li W; Feng J; Chen K; Tao M
Oncol Res; 2015; 22(2):67-74. PubMed ID: 25706393
[TBL] [Abstract][Full Text] [Related]
14. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis.
Wang ZX; Cao JX; Wang M; Li D; Cui YX; Zhang XY; Liu JL; Li JL
Cytotherapy; 2014 Jul; 16(7):934-45. PubMed ID: 24794183
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
16. A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer.
Zhu XP; Xu YH; Zhou J; Pan XF
Genet Mol Res; 2015 Aug; 14(3):10228-35. PubMed ID: 26345959
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer.
Wang S; Wang Z
Int Immunopharmacol; 2015 Sep; 28(1):22-8. PubMed ID: 26013109
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
19. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
20. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]